Co-culturing mesenchymal stem cells from bone marrow and periosteum enhances osteogenesis and neovascularization of tissue-engineered bone
Article first published online: 9 NOV 2011
Copyright © 2011 John Wiley & Sons, Ltd.
Journal of Tissue Engineering and Regenerative Medicine
Volume 6, Issue 10, pages 822–832, November 2012
How to Cite
Chen, D., Zhang, X., He, Y., Lu, J., Shen, H., Jiang, Y., Zhang, C. and Zeng, B. (2012), Co-culturing mesenchymal stem cells from bone marrow and periosteum enhances osteogenesis and neovascularization of tissue-engineered bone. J Tissue Eng Regen Med, 6: 822–832. doi: 10.1002/term.489
- Issue published online: 29 OCT 2012
- Article first published online: 9 NOV 2011
- Manuscript Accepted: 12 JUL 2011
- Manuscript Revised: 8 FEB 2011
- Manuscript Received: 27 AUG 2010
- human bone marrow mesenchymal stem cells;
- human periosteal-derived stem cells;
- bone tissue engineering;
Mesenchymal stem cells (MSCs) isolated from bone marrow and periosteum are often used as cellular sources for bone tissue engineering. This study showed that co-cultured human bone marrow stem cells (hBMSCs) and periosteal-derived stem cells (hPCs) resulted in a synergistic effect on osteogenic differentiation both in vitro and in vivo. Compared to hBMSCs and hPCs, co-culturing MSCs showed abundant mineralization, robust calcium deposition, steadily increasing ALP activity, and upgraded mRNA expression of osteogenic specific genes (COL1A1, BMP-2, osteopontin, osteocalcin) in vitro. Eight weeks after implantation of cellular β-TCP scaffolds in immunodeficient mice, similar synergistic effects were confirmed during in vivo evaluation of total new bone formation, mature bone formation, and neovascularization. Based on these findings, the use of co-cultured hBMSCs and hPCs can be recommended as a promising new approach for bone tissue engineering applications. Copyright © 2011 John Wiley & Sons, Ltd.